InduPro Announces Publication in Nature Establishing Spatial Protein Proximity as a New Framework for Therapeutic Discovery
InduPro, Inc., a biotechnology company harnessing protein proximity to create novel therapeutics for cancer and autoimmune diseases, today announced the publication in Nature of research establishing the spatial organization of cell-surface proteins as a new and therapeutically actionable dimension of disease biology.
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B financing and the dosing of the first patient in the Phase 1 clinical study of IDP-001, the company’s lead oncology program.
InduPro Therapeutics Appoints Amanda J. Redig, MD, PhD, as Chief Medical Officer
InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Amanda J. Redig, MD, PhD, as Chief Medical Officer. A medical oncologist and oncology drug developer, she brings extensive experience spanning academic medicine, drug development in both pharma and biotech, and life sciences investing.
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform
InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company (“Lilly”) to discover novel oncology treatments using InduPro’s proximity-guided platform.
InduPro Therapeutics Announces Strategic Investment from Sanofi and a Research Collaboration to Advance a Novel Bispecific for Autoimmune Disorders
InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inflammatory disorders.
